Why the study?
Does multifactorial treatment including RAS inhibition improve survival and renal prognosis in patients with type 2 diabetes and diabetic nephropathy compared to historical standard of care?
Population
543 patients with type 2 diabetes and diabetic nephropathy treated at the Steno Diabetes Center between…
Comparison
Current standard of care including… vs Historical cohort treated before implementation…
Design
Cohort
Follow-up
median 7.8 years for GFR decline; 5.7 years for…
Authors
Loading...
May support multifactorial care including RAS inhibition in diabetic nephropathy; leaves open causal confirmation in randomized trials.
Does multifactorial treatment including RAS inhibition improve survival and renal prognosis in patients with type 2 diabetes and diabetic nephropathy compared to historical standard of care?
Implementation of multifactorial treatment and RAS inhibition as standard of care significantly improved survival and slowed GFR decline in patients with type 2 diabetes and diabetic nephropathy.
Andrésdóttir et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: